MedWatch

Canada lures Novo and Lundbeck

Danish pharmaceutical groups are among the fastest growing companies in Canada. They are attracted by relatively high prices and an economy that was not left in ruins by the financial crisis.

Foto: Colourbox

The market may not be as big as the US. And it may not be growing as rapidly as China. Nevertheless, Canada has become an important market for Danish pharmaceutical companies, which are among the fastest growing outfits on the market.

That goes for the company Lundbeck, for example, which will break through the 1-billion-kroner-barrier (170 million USD) for Canadian turnover this year, making the Canadian market the group’s third-largest, only surpassed by Japan and the US.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier